Conversely, 18F-FDG PET/CT exhibited a higher SUVmax and allowed for the detection of more metastatic lesions in NPC, HER2+ BC, esophageal cancer, pancreatic cancer, and gynecological tumors. This evidence concerns the gene ERBB2 and nasopharyngeal carcinoma.